Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | Casein kinase II | 0.1071 | 0.4237 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.2365 | 1 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.2365 | 1 | 1 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.1071 | 0.4237 | 0.5 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.2365 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.1071 | 0.4237 | 0.0468 |
Plasmodium vivax | unspecified product | 0.1071 | 0.4237 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.1071 | 0.4237 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.1071 | 0.4237 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.2365 | 1 | 1 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.2365 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1071 | 0.4237 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.1071 | 0.4237 | 0.5 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.2365 | 1 | 1 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.1071 | 0.4237 | 0.5 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.2365 | 1 | 1 |
Leishmania major | casein kinase II, putative | 0.1071 | 0.4237 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.